一品红(300723.SZ)：AR882在国内审批预计2026年年中左右临床结束

Core Viewpoint - The company plans to submit the NDA for AR882 around mid-2026, following the completion of clinical trials and data organization [1] Group 1 - The expected timeline for the completion of clinical trials for AR882 is around mid-2026 [1] - After completing data organization and reporting, the company will submit the NDA, which is anticipated to take approximately 12-15 months for approval [1] - Upon successful approval of the NDA, the company will initiate commercialization of AR882, with efforts focused on efficient approval and rapid market launch [1]